T. Rowe Price Associates
LBRX

T. Rowe Price Associates’s LB Pharmaceuticals LBRX Stock Holding History

T. Rowe Price Associates’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$605K Buy
18,622
+5,393
+41% +$158K ﹤0.01% 2532
2026
Q1 		$327K Buy
13,229
+2,155
+19% +$49.7K ﹤0.01% 2645
2025
Q4 		$247K Sell
11,074
-271,570
-96% -$4.74M ﹤0.01% 2735
2025
Q3 		$4.46M Buy
+282,644
New +$4.48M ﹤0.01% 1429

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

T. Rowe Price Associates's LBRX Position: Q2 2026 in Review

T. Rowe Price Associates increased its LB Pharmaceuticals (LBRX) stake by 41% in Q2 2026, buying an estimated $158K and bringing the position to 18,622 shares worth $605K. The position accounts for ﹤0.01% of the portfolio, ranked #2532.

T. Rowe Price Associates first reported a position in LBRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.46M in Q3 2025. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • T. Rowe Price Associates held 18,622 shares of LB Pharmaceuticals worth $605K as of Q2 2026.
  • T. Rowe Price Associates bought 5,393 LB Pharmaceuticals shares in Q2 2026, an estimated $158K.
  • LB Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2532 holding.
  • T. Rowe Price Associates first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • T. Rowe Price Associates's LB Pharmaceuticals position peaked at $4.46M in Q3 2025.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.